Clinical trial

Fibrosis Lessens After Metabolic Surgery

NCT06374875

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-07-11

PhasePHASE4

Study timeline

Study start (actual)2024-07-11Date precision: day

Registry last updated2026-07-31

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)unresolved

Non-Alcoholic Fatty Liver Diseaseverified · MONDO: metabolic dysfunction-associated steatotic liver disease

Metabolic Dysfunction-Associated Steatohepatitis (MASH)unresolved

Liver Fibrosisunresolved

Obesityverified · MONDO: obesity disorder

Interventions

Metabolic surgeryPROCEDURE

Incretin-Based TherapyDRUG

Sponsors & collaborators

The Cleveland Cliniclead sponsor

Mapped research locations

LondonUnited Kingdom2 BarcelonaSpain1 ClevelandOhio, United States1 IndianapolisIndiana, United States1 PhoenixArizona, United States1 MilanItaly1 RochesterMinnesota, United States1 RomaItaly1 São PauloBrazil1 Mexico CityMexico1 DublinIreland1 BaselSwitzerland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06374875 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.